Esperion Therapeutics, Inc. Profile Avatar - Palmy Investing

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoi…

Drug Manufacturers - Specialty & Generic
US, Ann Arbor [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Esperion Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ESPR's Analysis
CIK: 1434868 CUSIP: 29664W105 ISIN: US29664W1053 LEI: - UEI: -
Secondary Listings
ESPR has no secondary listings inside our databases.